Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?

Chahine, Elias B.; Dougherty, John A.; Thornby, Krisy-Ann; Guirguis, Erenie

doi:10.1177/10600280211031390

Cited by 45 publications

(33 citation statements)

References 101 publications

(200 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…None of the structures shown in Figure 2 and Figure 3 meet this standard. All of the exploratory antibacterial antibiotics in current clinical trials have terrestrial origin [ 30 , 31 , 32 ]. However, the distinction between the marine and terrestrial origins of natural products must be done cautiously.…”

Section: Do Marine Organisms Biosynthesize Exceptional Inhibitors Of ...mentioning

confidence: 99%

β-Lactams from the Ocean

Fisher

Mobashery

2023

Marine Drugs

View full text Add to dashboard Cite

The title of this essay is as much a question as it is a statement. The discovery of the β-lactam antibiotics—including penicillins, cephalosporins, and carbapenems—as largely (if not exclusively) secondary metabolites of terrestrial fungi and bacteria, transformed modern medicine. The antibiotic β-lactams inactivate essential enzymes of bacterial cell-wall biosynthesis. Moreover, the ability of the β-lactams to function as enzyme inhibitors is of such great medical value, that inhibitors of the enzymes which degrade hydrolytically the β-lactams, the β-lactamases, have equal value. Given this privileged status for the β-lactam ring, it is therefore a disappointment that the exemplification of this ring in marine secondary metabolites is sparse. It may be that biologically active marine β-lactams are there, and simply have yet to be encountered. In this report, we posit a second explanation: that the value of the β-lactam to secure an ecological advantage in the marine environment might be compromised by its close structural similarity to the β-lactones of quorum sensing. The steric and reactivity similarities between the β-lactams and the β-lactones represent an outside-of-the-box opportunity for correlating new structures and new enzyme targets for the discovery of compelling biological activities.

show abstract

Section: Do Marine Organisms Biosynthesize Exceptional Inhibitors Of ...mentioning

confidence: 99%

β-Lactams from the Ocean

Fisher

Mobashery

2023

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…For Europe alone, this attributed to a cost of 1.5 billion Euros in healthcare-associated expenses and productivity loss ( Anderson et al., 2019 ). Furthermore, only 17 new antimicrobials have been approved for use in the past decade ( Chahine et al., 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems

Blasey

Rehrmann²,

Riebisch³

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Infections caused by Gram-negative pathogens pose a major health burden. Both respiratory and gastrointestinal infections are commonly associated with these pathogens. With the increase in antimicrobial resistance (AMR) over the last decades, bacterial infections may soon become the threat they have been before the discovery of antibiotics. Many Gram-negative pathogens encode virulence-associated Type III and Type IV secretion systems, which they use to inject bacterial effector proteins across bacterial and host cell membranes into the host cell cytosol, where they subvert host cell functions in favor of bacterial replication and survival. These secretion systems are essential for the pathogens to cause disease, and secretion system mutants are commonly avirulent in infection models. Hence, these structures present attractive targets for anti-virulence therapies. Here, we review previously and recently identified inhibitors of virulence-associated bacterial secretions systems and discuss their potential as therapeutics.

show abstract

“…The discovery of antibiotics is considered the most significant achievement known to man in the modern era. Despite having a limited spectrum and nature, they contributed to saving many lives during World War II [ 1 ]. Unfortunately, bacteria have developed and acquired strategies to resist antibiotics.…”

Section: Introductionmentioning

confidence: 99%

Antibacterial and Antivirulence Activities of Acetate, Zinc Oxide Nanoparticles, and Vitamin C Against E. coli O157:H7 and P. aeruginosa

Hamed

Emara

2023

Curr Microbiol

View full text Add to dashboard Cite

Infectious diseases remain one of the major health challenges worldwide due to the problem of antimicrobial resistance. Conventional antimicrobials have the disadvantage that bacteria rapidly acquire resistance to them, so alternatives must be developed to combat antibiotic resistance. Nanotechnology and the repurposing of existing drugs with known biological profiles are new approaches to replacing conventional antimicrobials. In this paper, we have tested the antibacterial activity of sodium acetate (NaA), vitamin C (VC), and zinc oxide nanoparticles (ZnO NPs) against Escherichia coli O157:H7 ATCC 51659 and Pseudomonas aeruginosa ATCC 27853. MIC values for tested compounds ranged from 0.08 to 6.5 mg ml−1, and the effect of combinations and safety profiles against HepG2 cell line of these compounds were also evaluated. At sub-MIC values, tested compounds had a potential antivirulence effect by inhibiting motility and reducing biofilm formation and maturation. Collectively, ZnO NPs and VC are considered safe alternatives to traditional antibiotics that are capable of reducing the development of antibiotic resistance in microbes. Graphical Abstract Graphical abstract representing the main aim and the final findings of our work. Spread of multidrug-resistant (MDR) bacterial strains created an urge for alternative safe antimicrobial agents. In this work, we found that ZnO NPs and vitamin C are potential candidates that could be used against MDR E.coli and P. aeruginosa.

show abstract

Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?

Cited by 45 publications

References 101 publications

β-Lactams from the Ocean

β-Lactams from the Ocean

Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems

Antibacterial and Antivirulence Activities of Acetate, Zinc Oxide Nanoparticles, and Vitamin C Against E. coli O157:H7 and P. aeruginosa

Contact Info

Product

Resources

About